Pluristem Therapeutics (PSTI) Receives $8M Grant for Phase III Critical Limb Ischemia Study
Tweet Send to a Friend
Pluristem Therapeutics Inc. (Nasdaq: PSTI) announced that its critical limb ischemia (CLI) program in the European Union has been awarded ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE